EWA
OTLK icon

Exencial Wealth Advisors’s Outlook Therapeutics OTLK Stock Holding History

Exencial Wealth Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-761
Closed -$26.5K – 432
2023
Q2 		$26.5K Buy
+761
New +$20.7K ﹤0.01% 427

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

Exencial Wealth Advisors's OTLK Position: Q3 2023 in Review

Exencial Wealth Advisors sold out of Outlook Therapeutics (OTLK) in Q3 2023, closing a stake of 761 shares — an estimated $26.5K sold.

Exencial Wealth Advisors first reported a position in OTLK in Q2 2023 and held it in 1 quarter. The position peaked at $26.5K in Q2 2023. 81 funds tracked by Wall St. Rank hold OTLK as of Q3 2023.

  • Exencial Wealth Advisors reported no remaining Outlook Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Exencial Wealth Advisors sold 761 Outlook Therapeutics shares in Q3 2023, an estimated $26.5K.
  • Exencial Wealth Advisors first reported a position in Outlook Therapeutics in Q2 2023 and held it in 1 quarter.
  • Exencial Wealth Advisors's Outlook Therapeutics position peaked at $26.5K in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2023.

Based on Exencial Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.